About Inhibitor of Bruton tyrosine kinase
Inhibitor of Bruton tyrosine kinase (IBTK) is a protein
from Homo sapiens identified by UniProt accession
Q9P2D0, 1353 residues long.
MolForge cross-references it against 0 known binders and
95 disease associations.
Target properties
| Protein name | Inhibitor of Bruton tyrosine kinase |
|---|
| UniProt accession | Q9P2D0 |
|---|
| Gene | IBTK |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1353 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (95)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- intraocular pressure measurement · score 0.27
- central corneal thickness · score 0.24
- DNA methylation · score 0.24
- corneal topography · score 0.20
- corneal resistance factor · score 0.16
- alcohol drinking · score 0.16
- coronary artery disease · score 0.14
- heel bone mineral density · score 0.13
- neurofibrillary tangles measurement · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9P2D0-F1 | alphafold | PREDICTED | 70.71 | — |
Amino-acid sequence (1353 residues)
MSSPMPDCTS KCRSLKHALD VLSVVTKGSE NQIKAFLSSH CYNAATIKDV FGRNALHLVS SCGKKGVLDW LIQKGVDLLV KDKESGWTAL HRSIFYGHID CVWSLLKHGV SLYIQDKEGL SALDLVMKDR PTHVVFKNTD PTDVYTWGDN TNFTLGHGSQ NSKHHPELVD LFSRSGIYIK QVVLCKFHSV FLSQKGQVYT CGHGPGGRLG HGDEQTCLVP RLVEGLNGHN CSQVAAAKDH TVVLTEDGCV YTFGLNIFHQ LGIIPPPSSC NVPRQIQAKY LKGRTIIGVA AGRFHTVLWT REAVYTMGLN GGQLGCLLDP NGEKCVTAPR QVSALHHKDI ALSLVAASDG ATVCVTTRGD IYLLADYQCK KMASKQLNLK KVLVSGGHME YKVDPEHLKE NGGQKICILA MDGAGRVFCW RSVNSSLKQC RWAYPRQVFI SDIALNRNEI LFVTQDGEGF RGRWFEEKRK SSEKKEILSN LHNSSSDVSY VSDINSVYER IRLEKLTFAH RAVSVSTDPS GCNFAILQSD PKTSLYEIPA VSSSSFFEEF GKLLREADEM DSIHDVTFQV GNRLFPAHKY ILAVHSDFFQ KLFLSDGNTS EFTDIYQKDE DSAGCHLFVV EKVHPDMFEY LLQFIYTDTC DFLTHGFKPR IHLNKNPEEY QGTLNSHLNK VNFHEDDNQK SAFEVYKSNQ AQTVSERQKS KPKSCKKGKN IREDDPVRML QTVAKKFDFS NLSSRLDGVR FENEKINVIA KNTGNKLKLS QKKCSFLCDV TMKSVDGKEF PCHKCVLCAR LEYFHSMLSS SWIEASSCAA LEMPIHSDIL KVILDYLYTD EAVVIKESQN VDFICSVLVV ADQLLITRLK EICEVALTEK LTLKNAAMLL EFAAMYSAKQ LKLSCLQFIG LNMAALLEAR SLDVLSDGVL KDLSEFYRKM IPAMDRRVIT PYQDGPDISY LEVEDGDIFL KEEINMEQNH SETMFKKAKT KAKKKPRKRS DSSGGYNLSD IIQSPSSTGL LKSGKTNSVE SLPELLTSDS EGSYAGVGSP RDLQSPDFTT GFHSDKIEAK VKPYVNGTSP VYSREDLKPW EKSPILKISA PQPIPSNRID TTSSASWVAG SFSPVSPPVV DLRTIMEIEE SRQKCGATPK SHLGKTVSHG VKLSQKQRKM IALTTKENNS GMNSMETVLF TPSKAPKPVN AWASSLHSVS SKSFRDFLLE EKKSVTSHSS GDHVKKVSFK GIENSQAPKI VRCSTHGTPG PEGNHISDLP LLDSPNPWLS SSVTAPSMVA PVTFASIVEE ELQQEAALIR SREKPLALIQ IEEHAIQDLL VFYEAFGNPE EFVIVERTPQ GPLAVPMWNK HGC
Explore Inhibitor of Bruton tyrosine kinase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets